The cloning & mutagenesis market size was valued at USD 3.48 billion in 2025 and is projected to grow from USD 4.03 billion in 2026 to USD 13.27 billion by 2034, registering a CAGR of 16.07% during the forecast period (2026–2034). North America dominated the cloning & mutagenesis marketwith a marketshare of 40.23% in 2025.
Cloning and mutagenesis technologies are molecular biology techniques used to replicate DNA fragments and introduce targeted genetic modifications for research, therapeutic development, and biotechnology applications. These technologies enable scientists to study gene function, develop recombinant products, and create genetically modified organisms with improved characteristics. Cloning and mutagenesis are widely used in pharmaceutical research, synthetic biology, vaccine development, and academic research.
The cloning & mutagenesis market demand is increasing due to expanding genomics research, rising investments in biotechnology and drug discovery, and growing adoption of gene editing technologies. Continuous advancements in cloning methods, increasing research funding, and expanding applications in personalized medicine and synthetic biology are further supporting cloning & mutagenesis market growth.
Download a Free Sample to Explore Detailed Market Insights
The cloning & mutagenesis market is highly exposed to supply chain disruptions because it depends on globally sourced enzymes, cloning kits, competent cells, plasmid vectors, PCR reagents, sequencing consumables, and temperature-sensitive laboratory materials that require strict quality control and cold chain logistics. Disruptions in these supplies increase manufacturing lead times, delay deliveries to research institutions, biotechnology companies, and pharmaceutical laboratories, and raise procurement costs, affecting research timelines and product development activities worldwide. The market is expected to witness an elastic supply chain recovery, supported by diversified global reagent suppliers, scalable manufacturing capacity, and sustained demand from biotechnology, pharmaceutical, and genomics research. Increasing investments in gene editing, synthetic biology, and cell and gene therapy are further strengthening supply chain resilience and enabling faster recovery from temporary disruptions.
The increasing demand for faster gene construct development is driving the transition from manual cloning workflows to automated high-throughput platforms. Research institutions and biopharmaceutical companies are adopting robotic liquid handling systems and automated cloning technologies to improve reproducibility, reduce turnaround times, and accelerate drug discovery and synthetic biology projects. This trend is enhancing laboratory efficiency while supporting large-scale genomics research.
The growing complexity of genetic engineering is accelerating the adoption of AI-powered sequence design and optimization tools. Researchers are increasingly using artificial intelligence to design cloning strategies, optimize primers, predict mutation outcomes, and improve protein engineering efficiency. This transition reduces experimental errors, shortens development cycles, and enhances research productivity across biotechnology and pharmaceutical applications.
The cloning & mutagenesis market forecasts continued investments toward expanding gene editing, synthetic biology, and plasmid DNA technology platforms to support advanced life science research and therapeutic development. Funding is also expected to accelerate automation, high-throughput molecular biology workflows, and next-generation cloning and mutagenesis tools that improve research efficiency and scalability.
Key Investment and Funding Activities in Cloning & Mutagenesis Market, 2025–2026
Rainbow Crops
≈USD 11.2 Million Seed
In June 2026, Rainbow Crops raised funds to scale its AI-driven multiplex genome editing platform, accelerating crop engineering programs that depend on cloning and mutagenesis technologies.
Neion Bio
USD 23 Million
In June 2026, Neion Bio closed an oversubscribed USD 23 million Series A to expand its biologics manufacturing platform and product pipeline, supporting advanced molecular engineering applications.
bit.bio
USD 50 Million
In January 2026, bit.bio raised USD 50 million led by M&G, together with a USD 20 million venture debt facility from BlackRock, to expand synthetic biology platforms and commercial cell engineering technologies.
Cassidy Bio
USD 8 Million
In November 2025, Cassidy Bio raised USD 8 million to develop next-generation gene editing technologies requiring extensive cloning and mutagenesis workflows during construct optimization.
Cirrus Therapeutics
USD 11 Million
In October 2025, Cirrus Therapeutics raised USD 11 million in seed financing to advance gene therapy programs using molecular cloning and mutagenesis during vector engineering.
ReciBioPharm
USD 100 Million
In May 2025, ReciBioPharm announced a USD 100 million investment to expand biologics manufacturing capabilities, including plasmid DNA and cell & gene therapy production that relies extensively on cloning technologies.
Telesis Bio
USD 21 Million
In February 2025, Telesis Bio secured a USD 21 million private placement to strengthen commercial operations and expand its automated DNA synthesis platform, supporting synthetic biology and molecular cloning workflows.
Expansion of Synthetic DNA Assembly and Rising Engineering of Next-generation Therapeutic Proteins Drives Market
The rapid adoption of synthetic DNA assembly and multi-fragment cloning techniques is driving demand for advanced cloning and mutagenesis technologies. Researchers increasingly require seamless assembly methods such as Gibson Assembly and Golden Gate cloning to construct complex plasmids and metabolic pathways for synthetic biology and cell engineering. This shift is encouraging laboratories to adopt high-efficiency cloning kits, high-fidelity enzymes, and automated assembly workflows that reduce experimental time while improving cloning accuracy and scalability.
The growing focus on engineering therapeutic proteins with improved efficacy, stability, and specificity is significantly increasing the use of saturation mutagenesis platforms. Pharmaceutical and biotechnology companies are performing large-scale protein variant screening to optimize monoclonal antibodies, enzymes, and biologics, driving demand for advanced mutagenesis reagents and high-throughput workflows. In 2025, Absci announced expanded AI-driven biologics discovery programs integrating high-throughput mutagenesis libraries with generative AI to accelerate therapeutic antibody optimization, highlighting the increasing commercial adoption of mutation-based protein engineering platforms.
Intellectual Property Restrictions and Performance Variability of Cloning and Mutagenesis Reagents Restrain Market Expansion
The cloning & mutagenesis market faces restraints due to the extensive patent protection surrounding proprietary cloning enzymes, vectors, recombination systems, and DNA assembly chemistries. Commercial laboratories and biotechnology companies often require licensing agreements to access specific cloning technologies, increasing operational costs and limiting flexibility in workflow selection. These intellectual property barriers particularly affect small biotechnology firms and academic spin-offs seeking to commercialize novel gene engineering products while maintaining competitive development timelines.
Cloning and mutagenesis workflows frequently encounter reduced efficiency when working with GC-rich sequences, repetitive DNA regions, large plasmids, or structurally complex genes. Such sequence-dependent variability often requires repeated optimization of primers, enzymes, vectors, and reaction conditions, increasing experimental costs and extending development timelines. This technical limitation restricts workflow standardization, particularly in high-throughput synthetic biology, protein engineering, and industrial biotechnology applications where reproducibility and cloning efficiency are essential for scalable research and commercial production.
Commercial Expansion of DNA Data Storage and Increasing R&D in Multiplex Genome-Scale Variant Libraries Offer Growth Opportunities to Market Players
The emergence of DNA data storage is creating a specialized opportunity for cloning & mutagenesis solution providers. Research organizations and technology companies require highly accurate plasmid construction, error-corrected DNA assembly, and sequence validation workflows to encode and retrieve digital information in DNA molecules. This creates growth opportunities for manufacturers of ultra-high-fidelity cloning enzymes, DNA assembly kits, and long-fragment vectors. Companies such as Twist Bioscience and Catalog Technologies are actively investing in DNA-based information storage, supporting future demand for advanced cloning technologies.
The rapid adoption of multiplex variant library generation is creating a niche opportunity for mutagenesis technology providers. Pharmaceutical companies increasingly generate thousands of gene variants simultaneously to study protein function, drug resistance, and pathogenic mutations using deep mutational scanning. This creates opportunities for suppliers offering saturation mutagenesis kits, pooled cloning systems, and automated library preparation solutions. Companies including New England Biolabs and Integrated DNA Technologies are expanding products that support large-scale variant library construction for next-generation functional genomics.
Shortage of Skilled Molecular Biology Professionals and Difficulty in Standardized Workflows Challenges Market Growth
The transition toward automated cloning, multiplex mutagenesis, and integrated bioinformatics workflows requires specialized expertise that many research laboratories and emerging biotechnology companies lack. Shortages of professionals with experience in advanced molecular engineering, automation, and computational biology delay technology adoption and reduce utilization of sophisticated cloning platforms. For example, the expanding demand for skilled synthetic biology scientists has outpaced workforce availability across major biotechnology hubs, slowing implementation of advanced laboratory workflows.
Large pharmaceutical companies and contract research organizations often operate multiple research sites using different cloning protocols, laboratory automation systems, and quality management practices. This lack of workflow harmonization creates inconsistencies in experimental reproducibility, data comparability, and technology transfer between facilities. As collaborative multi-site drug discovery programs expand globally, these operational differences increase validation requirements, extend project timelines, and slow the broader adoption of standardized cloning and mutagenesis platforms.
By product, the cloning kits segment accounted for a share of 36.06% in 2025, owing to their compatibility with seamless DNA assembly workflows, availability of application-specific kits for diverse host systems, and reduced laboratory time. These advantages improve cloning success rates, simplify protocol standardization, and accelerate recombinant DNA construct generation across research laboratories.
The mutagenesis kits segment is expected to grow at a CAGR of around 16.58% during the forecast period, driven by the rising demand for saturation mutagenesis libraries, expanding codon optimization studies, and increasing engineering of next-generation enzymes. These kits enable rapid sequence modification with high precision, supporting advanced protein engineering and functional genomics research.
By technology, the topo PCR cloning segment accounted for a share of 24.90%. It eliminates ligation steps, supports direct cloning of PCR amplicons, and delivers consistently high transformation efficiency. These advantages reduce workflow complexity and improve turnaround time for routine molecular cloning and gene characterization studies.
The site-directed mutagenesis segment is expected to grow at a CAGR of 16.93% during the forecast period, driven by increasing amino acid substitution studies, growing structure-function relationship analysis, and expanding therapeutic protein optimization. Its ability to introduce targeted genetic changes with exceptional accuracy supports biologics discovery and precision molecular engineering.
By end-user, biopharmaceutical & pharmaceutical companies accounted for a share of 40.27% in 2025 due to increasing plasmid-based biologics development, extensive recombinant protein pipeline activities, and continuous monoclonal antibody engineering programs. Their sustained R&D investments generate high demand for reliable cloning and mutagenesis technologies throughout therapeutic development.
The CROs & CMOs segment is expected to grow at a CAGR of 17.46% during the forecast period, driven by expanding custom vector construction services, rising outsourced gene engineering projects, and increasing demand for high-throughput mutation screening. Their scalable laboratory infrastructure enables faster project execution while reducing operational costs for biotechnology and pharmaceutical clients.
North America: Market Dominance Led by Strong Genomics Research Infrastructure and Growing Collaboration Between Academic Institutions
The North American cloning & mutagenesis market accounted for the largest regional share of 40.23% in 2025, driven by strong genomics research infrastructure, high investments in biopharmaceutical innovation, and widespread adoption of synthetic biology and gene engineering technologies. The region also benefits from advanced academic research institutions, established biotechnology clusters, and extensive funding for life science research. According to the National Institutes of Health, the US continued to support biomedical research with an annual budget exceeding USD 47 billion in FY2025, strengthening demand for advanced molecular biology technologies.
The US cloning & mutagenesis market was valued at USD 1.22 billion in 2025, driven by increasing biologics discovery programs, expanding gene editing research, and growing investments in synthetic biology platforms. Pharmaceutical companies, biotechnology firms, and academic research centers are continuously adopting advanced cloning and mutagenesis technologies for therapeutic protein engineering, recombinant DNA development, and functional genomics studies.
The Canada cloning & mutagenesis market size was valued at USD 176.20 million in 2025, supported by growing investments in genomics research, expanding biotechnology innovation programs, and growing collaboration between academic institutions and industry. Government-supported precision medicine initiatives and rising demand for molecular biology research tools are encouraging wider adoption of cloning and mutagenesis technologies.
Asia Pacific: Fastest Growth Driven by Expanding Biotechnology Manufacturing and Commercialization of Recombinant Biologics
The Asia Pacific cloning & mutagenesis market is expected to grow at a CAGR of 18.10% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding biotechnology manufacturing, increasing government investments in genomics and synthetic biology research, and rapid growth of contract research and biopharmaceutical development activities. Countries across the region are strengthening life science infrastructure and molecular biology capabilities. According to the Japan Agency for Medical Research and Development, Japan continues to expand funding for genome, regenerative medicine, and advanced biotechnology research, supporting broader adoption of cloning and mutagenesis technologies.
The China cloning & mutagenesis market size was valued at USD 201.87 million in 2025, supported by expansion of domestic biotechnology companies, increasing investments in synthetic biology, and growing commercialization of recombinant biologics. Government-backed innovation programs and expanding genomic research centers are accelerating the adoption of advanced cloning and mutagenesis platforms.
The India cloning & mutagenesis market size was valued at USD 103.25 million in 2025, fueled by the establishment of the country's first publicly funded biofoundry, implementation of the BioE3 Policy, and expansion of shared biofoundry infrastructure for synthetic biology and precision biomanufacturing. The launch of the National Biofoundry Network and Design-Build-Test-Learn platforms is accelerating demand for advanced cloning, plasmid engineering, and mutagenesis technologies across academia, startups, and industrial biotechnology.
The Japan cloning & mutagenesis market was valued at USD 119.13 million in 2025, supported by increasing commercialization of microbial cell factories, strong industrial enzyme engineering programs, and sustained government funding for translational genome engineering. Growing collaboration between pharmaceutical companies, universities, and contract research laboratories for high-throughput functional genomics and recombinant strain development continues to increase the adoption of sophisticated cloning and mutagenesis platforms.
The cloning & mutagenesis market competitive landscape is moderately consolidated, with competition led by established life science companies offering molecular biology reagents, cloning technologies, and integrated laboratory workflows. Leading players compete through high-fidelity cloning chemistries, advanced DNA assembly technologies, automation, and comprehensive product portfolios supporting genomics and synthetic biology research. Emerging companies differentiate themselves through AI-enabled sequence design, specialized high-fidelity mutagens, and enzyme engineering. The cloning & mutagenesis market ecosystem is shaped by continuous innovation in gene engineering, expanding synthetic biology applications, and growing demand for reproducible, high-throughput molecular biology solutions.
November 2025: Colossal Biosciences acquired ViaGen Pets, a commercial animal cloning company.
August 2025: Colossal Biosciences expanded internationally by establishing Colossal Australia through acquisition of the Thylacine Integrated Genomics Restoration Research Lab (TIGRR) at the University of Melbourne.
July 2025: Colossal Biosciences announced a collaboration with the Canterbury Museum and Ngāi Tahu to advance genomic reconstruction of the extinct moa using gene-editing and cloning technologies.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com